NAC
AntioxidantsPreclinicalAlso known as: N-Acetylcysteine, N-Acetyl-L-Cysteine, Acetylcysteine, Mucomyst, Acetadote, Fluimucil, Parvolex, NALC, L-α-Acetamido-β-mercaptopropionic acid
N-acetylcysteine (NAC) is the acetylated form of the amino acid L-cysteine — a small thiol-containing molecule that serves as a rate-limiting precursor for glutathione (GSH) synthesis and, independently, as a direct antioxidant and mucolytic agent. Discovered in the 1960s as a mucolytic (via its ability to cleave disulfide bonds in mucus glycoproteins) and repurposed in the mid-1970s as the definitive antidote for acetaminophen (paracetamol) overdose, NAC has one of the broadest therapeutic profiles of any thiol-based medication and is on the World Health Organization's List of Essential Medicines.
Overview
At A Glance
NAC's mechanism of action operates through at least four distinct but overlapping pathways, and understanding which pathway dominates in a given clinical context is essential for predicting whether supplementation will actually help. The four pathways are (1) glutathione precurso…
Mechanism of Action
NAC's mechanism of action operates through at least four distinct but overlapping pathways, and understanding which pathway dominates in a given clinical context is essential for predicting whether supplementation will actually help. The four pathways are (1) glutathione precursor supply, (2) direct antioxidant and reactive species scavenging, (3) mucolytic disulfide bond reduction, and (4) glutamate modulation in the central nervous system.
Pathway 1: Glutathione precursor supply. This is the dominant mechanism in most clinical contexts. Glutathione synthesis is a two-step ATP-dependent process: γ-glutamylcysteine synthetase (GCL, the rate-limiting enzyme) combines glutamate and cysteine, and glutathione synthetase adds glycine to form the tripeptide GSH (γ-Glu-Cys-Gly). Cysteine is the rate-limiting substrate — its intracellular free concentration is low (0.1-0.2 mM versus glutamate at 5-15 mM and glycine at 1-5 mM), its synthesis from methionine via the transsulfuration pathway is slow, and GCL has a Km for cysteine close to physiological concentrations so small changes in cysteine availability produce large changes in GSH synthesis rate. NAC is deacetylated intracellularly by cytosolic aminoacylases, releasing free cysteine that immediately enters the GSH synthesis pathway. This is the molecular basis for NAC's acetaminophen-overdose antidote effect (urgent restoration of depleted hepatic GSH), its protective effect against ischemia-reperfusion injury (GSH depletion is a feature of reperfusion), and much of its psychiatric and anti-inflammatory effects (inflammation consumes GSH and NAC replenishes it). The clinical implication is that NAC's benefit is largest in contexts where GSH is depleted — healthy, well-fed individuals with normal GSH status derive less benefit from supplementation than do patients with oxidative stress, chronic inflammation, or direct GSH-depleting exposures.
Pathway 2: Direct antioxidant and reactive species scavenging. NAC's free sulfhydryl group can directly scavenge reactive oxygen and nitrogen species (ROS/RNS), most importantly hydroxyl radical (•OH), hypochlorous acid (HOCl), and nitrogen dioxide (•NO2), along with secondary reactive aldehydes like 4-hydroxynonenal (4-HNE). The direct-scavenging rate constants for NAC are substantially lower than those of GSH for most ROS, so this pathway contributes less than the GSH-restoration pathway quantitatively, but it is operative at the doses used clinically (plasma NAC concentrations after 600-1200 mg oral doses reach the low micromolar range, and IV doses are much higher). The direct-antioxidant action also contributes to NAC's protection against heavy metal toxicity via formation of less-reactive metal-thiol adducts.
Pathway 3: Mucolytic disulfide bond reduction. Mucus glycoproteins (mucins) contain large numbers of disulfide bonds (-S-S-) that cross-link mucin polymers into the viscous mucus gel. NAC's free thiol can reduce these disulfide bonds, converting them to pairs of free sulfhydryl groups and depolymerizing the mucin network. The clinical consequence is less viscous, more easily cleared mucus — the mechanism underlying NAC's use in cystic fibrosis, COPD, bronchiectasis, and acute mucostasis. Inhaled NAC is specifically designed to exploit this local effect without requiring systemic absorption. Nebulized NAC has a characteristic sulfur smell from hydrogen sulfide released as disulfide bonds break. Oral high-dose NAC also has mucolytic activity via systemic delivery to airway mucus, which is the basis for the COPD evidence base.
Pathway 4: Glutamate modulation in the central nervous system. This is the most recently characterized and possibly the most important pathway for NAC's psychiatric effects. NAC (and the cysteine released from NAC) activates the cystine-glutamate antiporter system Xc- (SLC7A11/SLC3A2), which imports cystine from extracellular space in exchange for glutamate export. This antiport reduces synaptic glutamate levels, activates presynaptic metabotropic glutamate receptor 2/3 (mGluR2/3) autoreceptors, and inhibits further glutamate release from neurons — effectively producing a feedback modulation of glutamatergic neurotransmission. This mechanism is thought to underlie NAC's benefits in cocaine addiction (cocaine produces excessive glutamatergic tone in reward circuits), obsessive-compulsive disorder (glutamate dysregulation in corticostriatal circuits), bipolar depression (glutamate abnormalities in depression), and trichotillomania/body-focused repetitive behaviors (nucleus accumbens glutamate involvement). The mechanism also provides a framework for understanding why NAC's psychiatric effects develop over weeks rather than hours — the glutamate-modulation effect requires sustained changes in system Xc- activity and presynaptic receptor sensitivity, not acute receptor binding.
Pharmacokinetics: NAC has poor oral bioavailability as an intact molecule — approximately 4-10% — due to extensive first-pass metabolism in the gut wall and liver. This fact is often used to argue that oral NAC "doesn't work," but it is misleading because NAC's therapeutic effect is largely mediated by the cysteine it delivers, not by the intact NAC molecule itself. Oral NAC raises plasma cysteine and cysteine-containing mixed disulfides substantially (3-5 fold at typical doses), and tissues with active thiol uptake (liver, lung, brain) see even larger percentage increases in cysteine delivery and GSH synthesis rate. Plasma half-life of intact NAC is approximately 6 hours; peak concentrations occur 1-2 hours after oral dosing. NAC is not a substrate for cytochrome P450 enzymes, giving it an exceptionally clean drug-drug interaction profile. Elimination is via renal excretion (both free NAC and metabolites including taurine, sulfate, and cysteine) and some metabolism to inorganic sulfate. IV administration bypasses first-pass metabolism and produces substantially higher systemic exposure than oral dosing, which is why IV protocols are used in acetaminophen overdose where rapid and complete restoration of hepatic GSH is time-critical.
Tissue distribution: NAC and its released cysteine distribute broadly. The liver is the highest-exposure organ due to first-pass kinetics. Lung tissue achieves meaningful concentrations after oral dosing, which is relevant for the COPD indication. The brain is a more complicated compartment — NAC itself crosses the blood-brain barrier poorly, but cysteine (released from NAC in plasma and liver) crosses readily via neutral amino acid transporters, and the brain can also use NAC's cysteine to raise astrocytic GSH, which is then exported to neurons as cysteine-glycine (via γ-glutamyl transpeptidase and aminopeptidase N). The brain-distribution data help reconcile psychiatric efficacy of oral NAC with the molecule's modest direct CNS penetration.
Overview
N-acetylcysteine (NAC) is the acetylated form of the amino acid L-cysteine — a small thiol-containing molecule that serves as a rate-limiting precursor for glutathione (GSH) synthesis and, independently, as a direct antioxidant and mucolytic agent. Discovered in the 1960s as a mucolytic (via its ability to cleave disulfide bonds in mucus glycoproteins) and repurposed in the mid-1970s as the definitive antidote for acetaminophen (paracetamol) overdose, NAC has one of the broadest therapeutic profiles of any thiol-based medication and is on the World Health Organization's List of Essential Medicines. It is available in multiple regulatory categories depending on jurisdiction: prescription (for IV use in acetaminophen overdose and inhalation/nebulization for mucolytic use), over-the-counter (in much of Europe as oral effervescent tablets branded Fluimucil, ACC, Mucomyst), and as a dietary supplement (in the United States, where it has been sold as a supplement for decades despite a contentious 2020 FDA enforcement notice asserting that NAC's status as a drug — approved 1963 — precludes supplement classification under DSHEA; the FDA walked back enforcement in 2022 and supplement sales resumed, though the legal question technically remains unresolved).
Structurally, NAC is L-cysteine with an acetyl group on its amine nitrogen — a simple modification that dramatically improves stability (the free thiol of unmodified cysteine oxidizes rapidly), reduces the taste problem (cysteine is intensely unpleasant), and modestly improves oral tolerability. The acetyl group is cleaved by intracellular deacetylases after uptake, releasing free cysteine into the cellular cysteine pool, where it enters the two-step enzymatic synthesis of glutathione: cysteine + glutamate → γ-glutamylcysteine (by γ-glutamylcysteine synthetase, the rate-limiting enzyme) → GSH (by glutathione synthetase, adding glycine). Because cysteine is rate-limiting for GSH synthesis in most tissues — cysteine is the least abundant of the three GSH amino acids in the free amino acid pool, and its intracellular concentration tracks closely with GSH synthesis rate — delivering cysteine via NAC can meaningfully raise tissue GSH in contexts where GSH is depleted. This is the molecular basis for NAC's acetaminophen antidote effect: acetaminophen overdose generates the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI) faster than hepatic GSH can conjugate it, GSH is consumed, and hepatocyte death follows unless GSH synthesis is urgently restored by providing exogenous cysteine.
The clinical use cases for NAC divide into three tiers by strength of evidence. Tier 1 (strong RCT evidence): acetaminophen overdose (IV NAC via the 21-hour Prescott/Smilkstein protocol or the 72-hour oral Smilkstein protocol — mortality reduction from ~5% to <1% when given within 8-10 hours of ingestion); chronic obstructive pulmonary disease exacerbation reduction (BRONCUS trial and subsequent Cochrane reviews showing modest reductions in exacerbation frequency with high-dose oral NAC, 600-1200 mg/day); idiopathic pulmonary fibrosis (mixed results — earlier IFIGENIA trial was positive, later PANTHER-IPF trial was negative for triple therapy but NAC monotherapy remained in the protocol); contrast-induced nephropathy prevention (large meta-analyses show modest benefit, though the ACT trial called the effect into question and modern practice emphasizes hydration more than NAC). Tier 2 (promising but heterogeneous): psychiatric applications including bipolar depression (Berk 2008, 3-month RCT showing significant improvement in depression and functional outcomes versus placebo); obsessive-compulsive disorder and OCD-spectrum disorders like trichotillomania and nail-biting (Grant 2009 trichotillomania RCT positive, subsequent OCD trials mixed); schizophrenia (Berk 2008 negative symptoms improvement; later trials heterogeneous); cocaine, cannabis, and gambling addiction (signal for cannabis and early-abstinence cocaine, weaker for gambling); Alzheimer's and Parkinson's disease (preclinical and small-trial rationale, no definitive evidence); male infertility (Ciftci 2009 showing improved sperm parameters in idiopathic oligoasthenoteratozoospermia); polycystic ovary syndrome (Rizk 2005, Fulghesu 2002 showing improved insulin sensitivity and ovulation). Tier 3 (mechanism-driven but not rigorously tested in humans): generalized "antioxidant supplementation" in healthy individuals, "detox" protocols, alcohol hangover prevention, exercise performance or recovery support, sleep support (NAC is sometimes promoted for sleep, though the evidence is weak), and broad longevity support as a GSH-preserving agent — these uses are empirical and driven primarily by mechanism rather than by direct clinical data in healthy populations.
NAC is one of the most-studied thiol therapies in medicine, with over 15,000 PubMed-indexed publications and active investigation across dozens of additional indications including COVID-19 (mostly negative for acute infection, some signal for long COVID symptoms), post-traumatic stress disorder (small trials, promising), autism spectrum disorder (irritability and repetitive behaviors), sickle cell disease, radiation-induced toxicity prevention, and aminoglycoside-induced hearing loss. The combination of low cost (typical oral dose costs pennies per day), favorable safety profile (side effects are almost entirely limited to gastrointestinal upset at high doses and rare anaphylactoid reactions to IV infusion, which are rate-dependent rather than truly allergic), wide availability, and coherent mechanistic rationale has made NAC one of the workhorses of off-label psychiatric and biohacker medicine. This entry covers NAC's glutathione-precursor and direct-antioxidant mechanisms, the pharmacokinetic peculiarities (oral bioavailability is only 4-10% as intact NAC, though effective for raising cysteine pools), the established acetaminophen-overdose and COPD/mucolytic evidence, the psychiatric and addiction medicine literature, the male fertility and PCOS data, practical dosing by indication, the 2020 FDA regulatory episode and its implications, appropriate stacking with other antioxidants and glutathione-pathway nutrients, the relatively narrow but real contraindication set, and the honest framing that distinguishes where NAC has strong evidence (overdose, mucolytic, specific psychiatric conditions) from where it is being taken on faith (general "antioxidant" supplementation in healthy people).
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
- Documented hypersensitivity to NAC or any component of the formulation — rare true hypersensitivity reactions preclude further use.
- Active upper GI bleeding or severe peptic ulcer disease — NAC's mild mucosal irritation may exacerbate bleeding lesions; use with caution or avoid during active bleeding.
Relative contraindications and use with caution:
- Asthma with unstable bronchospasm (nebulized NAC specifically) — nebulized NAC can provoke bronchospasm; always pretreat with bronchodilator and use in monitored setting. Oral NAC is generally safe in asthma.
- Severe renal impairment (eGFR < 30) — NAC is renally excreted; accumulation is theoretically possible. Dose adjustment may be prudent, though NAC's wide therapeutic window usually obviates concern.
- Severe hepatic impairment outside of the acetaminophen-overdose indication — paradoxically, acetaminophen overdose liver failure is the definitive indication for NAC. For non-overdose cirrhosis or hepatic failure, use with clinical judgment.
- Pregnancy (non-emergency use) — Category B; extensive emergency use in pregnancy has not identified teratogenicity, but non-emergency supplementation during pregnancy should be discussed with obstetric provider.
- Concurrent nitroglycerin or nitrate therapy — potentiated vasodilation and headache; monitor for symptomatic hypotension.
- Organ transplant patients on calcineurin inhibitors — no specific contraindication but all supplements in this population merit transplant-team discussion.
- Severe bipolar disorder — do not replace standard mood stabilizers with NAC; use only as adjunct under psychiatric care.
- Acute cocaine or stimulant intoxication — case reports of cardiovascular events with high-dose NAC plus stimulants; avoid until stimulant clearance confirmed.
Special populations:
- Pediatric use: IV for acetaminophen overdose is standard. For other indications, use under pediatric specialist guidance with weight-based dosing.
- Elderly: Well-tolerated. The GlyNAC protocol is specifically developed for older adults and shows good safety in that population.
- Athletes and competitive performers: Not on any banned substance lists. Acute high-dose NAC around training may blunt exercise adaptation (theoretical concern based on hormesis framework); consider timing away from training sessions.
- Patients on concurrent chemotherapy: NAC's antioxidant effects have raised theoretical concern about interference with chemotherapy mechanisms that depend on oxidative damage (some cytotoxic agents). Evidence is mixed; discuss with oncology team before combining.
Laboratory interference:
- NAC can cause false-positive ketone tests in urine (nitroprusside-based tests).
- May affect some thiol-based laboratory assays if drawn shortly after dosing.
- Does not typically interfere with standard drug screens.
When to seek medical attention:
- Severe allergic reaction (swelling of face/throat, severe rash, difficulty breathing)
- Persistent vomiting or severe GI symptoms
- New or worsening chest pain, severe dizziness (particularly if on nitrates)
- Bronchospasm or wheezing (particularly with nebulized NAC)
- Signs of severe hypersensitivity
When to discontinue:
- Persistent intolerable GI side effects despite dose reduction and food co-administration
- Allergic or anaphylactoid reaction
- No meaningful subjective or objective benefit after 8-12 week trial for a non-essential indication
- Planned surgery or invasive procedure (discuss with surgical team — NAC has mild platelet effects at high doses)
- Pregnancy (discuss continuation with obstetric provider)
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for NAC.
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsView Full Dosage Guide →
Protocols, calculator & safety for NAC
Related Articles
All PostsAquasome Nanotechnology and Oral Peptides: The Mechanism, the Research, and the 10 Compounds It Actually Works For
how aquasome 3-layer nano-encapsulation lets peptides like retatrutide, bpc-157, and tb-500 survive the gut. pubmed-backed deep dive on the 10 compounds it works for.
5/20/2026How to Make a Peptide Nasal Spray at Home — The Complete DIY Guide (2026)
Full DIY protocol for reconstituting peptides into nasal sprays — Semax, Selank, oxytocin, DSIP, BPC-157. Reconstitution math, sterile technique, storage, pH/tonicity, safety. 11-step protocol with worked examples.
4/21/2026We Compared 8 Focus Nootropics for 90 Days — Here's What Actually Works
We tested 8 popular focus nootropics over 90 days using objective metrics — reaction time, deep work hours, and daily focus ratings. Here are the honest results, including costs and side effects.
4/3/2026Research Score
0 PubMed studies
Quality Indicators
Data Completeness
50%Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is NAC and what does it actually do in the body?
NAC (N-acetylcysteine) is the acetylated form of the amino acid L-cysteine. Its primary mechanism is serving as a precursor to glutathione (GSH), the body's master intracellular antioxidant — cysteine is rate-limiting for GSH synthesis, so delivering NAC effectively delivers cysteine to tissues that need to make more GSH. It also directly scavenges reactive oxygen species, breaks disulfide bonds in mucus (making it a mucolytic), and modulates glutamate signaling in the brain via the cystine-glutamate antiporter. The most well-established clinical uses are (1) IV antidote for acetaminophen overdose, where restoring depleted hepatic GSH prevents liver failure (Prescott 1977, Smilkstein 1988, PMID 3201097), and (2) chronic mucolytic therapy for COPD (BRONCUS trial, Decramer 2005, PMID 15867039). Emerging uses include psychiatric adjunct therapy for bipolar depression, OCD-spectrum disorders, and trichotillomania (Berk 2008, PMID 18534116; Grant 2009, PMID 19581567), male fertility support (Ciftci 2009, PMID 19375649), and PCOS insulin sensitization.
How is NAC different from glutathione supplementation? Should I take both?
NAC is a glutathione precursor — it delivers cysteine, which your cells use to synthesize new GSH via the endogenous γ-glutamylcysteine synthetase and glutathione synthetase pathways. Direct glutathione supplementation (oral liposomal, intranasal, or IV) delivers the intact GSH molecule to blood and tissue pools. The two approaches are additive rather than redundant: NAC enables ongoing GSH synthesis where cysteine is limiting, while exogenous GSH provides immediate repletion of circulating and tissue pools without requiring synthesis. In acute GSH-depletion contexts (acetaminophen overdose, heavy toxicant exposure, severe oxidative stress), NAC is the first-line intervention because it sustains GSH synthesis over hours to days. For chronic supplementation, the combination of oral NAC (for synthesis support) plus liposomal or intranasal glutathione (for direct pool repletion) is a reasonable stack, though cost-benefit versus NAC alone is debatable for healthy individuals. See Glutathione for deeper discussion of exogenous GSH formulations and their bioavailability.
What dose of NAC should I take for general antioxidant support?
For general supplement-channel antioxidant support in a healthy adult, 600 mg once daily with food is the standard conservative dose — well-established through decades of use, low side-effect burden, and supported by the European OTC supplement framework. For clinical indications, doses vary substantially: 1200 mg/day for COPD adjunct therapy, 2000 mg/day for psychiatric adjunct therapy (Berk 2008 bipolar protocol used 1 gram twice daily), and up to 2400-3600 mg/day in some research protocols under clinical supervision. The GlyNAC longevity protocol developed by Baylor's Rajagopal Sekhar lab uses weight-based dosing of approximately 100 mg/kg/day NAC plus matched glycine (Kumar 2021, PMID 33877370). For most healthy individuals, doses above 1200 mg/day escalate GI side effects without clear additional benefit. Start low, take with food, divide if dosing above 600 mg/day, and assess tolerance before escalating.
Does NAC really help with psychiatric conditions or is it just supplement-industry marketing?
The psychiatric evidence for NAC is genuinely promising but heterogeneous. Berk et al. 2008 (PMID 18534116) conducted a well-designed 24-week placebo-controlled RCT of NAC 1 gram twice daily as adjunct to standard therapy in 75 bipolar patients and demonstrated significant improvement in depressive symptoms and functional outcomes — this is not supplement marketing, it is peer-reviewed RCT evidence from a reputable academic psychiatry group. Grant et al. 2009 (PMID 19581567) demonstrated significant reduction in hair-pulling symptoms with NAC 1200-2400 mg/day in trichotillomania. Berk also showed NAC benefit in schizophrenia negative symptoms (PMID 18436195). The Ooi et al. 2018 meta-analysis (PMID 29890589) found a modest overall effect across psychiatric indications with significant heterogeneity between disorders. The honest framing: NAC is not a psychiatric medication replacement, but the adjunct evidence for bipolar depression, trichotillomania, and early-abstinence cocaine use disorder is real and clinically meaningful. Current psychiatric practice increasingly uses NAC as a low-risk, low-cost adjunct for these specific conditions, while larger definitive trials continue. Discuss with prescribing psychiatrist — do not self-treat serious psychiatric conditions with supplements alone.
Is the GlyNAC protocol legitimate or just another supplement fad?
The GlyNAC (glycine + N-acetylcysteine) protocol was developed by Rajagopal Sekhar and colleagues at Baylor College of Medicine, based on the biochemical observation that older adults have reduced glutathione synthesis capacity due to BOTH reduced cysteine availability (addressed by NAC) and reduced glycine availability (glycine is the third GSH amino acid and is often intake-limited in older adults). Kumar et al. 2021 (PMID 33877370) conducted an open-label trial in 24 older adults (71-80 years) and 24 younger controls, administering GlyNAC for 16 weeks, and demonstrated corrections in glutathione levels, oxidative stress markers, mitochondrial function, insulin resistance, inflammation, endothelial function, gait speed, strength, and cognitive performance. Subsequent randomized placebo-controlled trial in older adults (Kumar 2023) confirmed many of these benefits. The evidence base is not yet the size of metformin or rapamycin research, but GlyNAC has legitimate peer-reviewed support for age-related decline in mitochondrial and redox function. The protocol uses pharmacological doses (~100 mg/kg/day of each amino acid) — this is substantially higher than casual supplement dosing and should be undertaken with clinical oversight. See Glycine and Glutathione for related discussion.
Why did the FDA try to ban NAC supplements in 2020, and can I still buy it?
In July 2020, the FDA issued warning letters to several supplement manufacturers asserting that NAC's status as a drug — first approved in 1963 for mucolytic use — precluded its classification as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA's 'prior drug exclusion' clause). This caused brief supplement-channel disruptions, particularly at Amazon. The FDA then went through a multi-year enforcement discretion process and in 2022 announced it would exercise enforcement discretion for NAC as a supplement pending a formal rulemaking decision, effectively restoring consumer availability. In 2022 and 2023, NAC supplements returned to standard retail channels and remain widely available in the United States and most other markets. The underlying legal question (does the prior-drug-exclusion apply to NAC) remains technically unresolved, but functionally NAC is available as both a prescription drug (IV for overdose, nebulized for mucolytic use) and a dietary supplement (oral capsules and tablets). Reputable suppliers include NOW Foods, Life Extension, Pure Encapsulations, Thorne, Designs for Health, and many others — look for third-party testing and product freshness.
Does NAC interact with my regular medications?
NAC has one of the cleanest drug-interaction profiles in pharmacology because it is not a substrate, inducer, or inhibitor of cytochrome P450 enzymes, which mediate most pharmaceutical drug interactions. Notable interactions to be aware of: (1) Nitroglycerin and organic nitrates — NAC potentiates nitrate-induced vasodilation and may increase headache and hypotension; particularly relevant for angina patients on chronic nitrates. (2) Activated charcoal — binds NAC and reduces its absorption; relevant only in the emergency department poisoning context when both are used. (3) High-dose NAC may have mild platelet-inhibitory effects at research doses (>3 g/day); modest concern for patients on anticoagulants or pre-surgical contexts. (4) Concurrent chemotherapy — theoretical concern about NAC interfering with cytotoxic agents that rely on oxidative damage; discuss with oncology team before combining. (5) Stimulants (particularly cocaine) — case reports of cardiovascular events; avoid during acute stimulant intoxication. Beyond these, NAC stacks cleanly with SSRIs, mood stabilizers, antipsychotics, metformin, statins, antihypertensives, most supplements, and most other prescription medications.
I heard NAC can blunt exercise adaptation — is this real and should I avoid it?
The exercise-adaptation concern is partially real but frequently overstated. Exercise-induced oxidative signaling (ROS generated in muscle during contraction and in response to training stimulus) drives adaptive responses including mitochondrial biogenesis, antioxidant enzyme upregulation, and skeletal muscle remodeling — the hormesis framework. High-dose antioxidants (vitamin C 1000+ mg, vitamin E 400+ IU, high-dose NAC) administered around training sessions have been shown in some studies to blunt these adaptive signals (Ristow 2009 is the classic paper on vitamin C/E blunting insulin-sensitization adaptations to exercise). For NAC specifically, acute pre-exercise NAC can blunt ROS signaling in a similar manner. The practical implications: (1) Athletes pursuing peak training adaptation should probably avoid high-dose NAC (>1200 mg/day) within 2-3 hours of key training sessions. (2) Post-exercise NAC is less concerning than pre-exercise NAC from an adaptation-signaling standpoint. (3) For people training recreationally, taking NAC for specific clinical indications, or working through illness or injury, the adaptation-blunting concern is much less important than the specific indication benefit. (4) Timing NAC for non-training days or well away from training windows is a reasonable compromise for athletes who want both adaptation and NAC's other benefits. This is the same framework that applies to CoQ10, high-dose vitamin C, and other antioxidants around training.
What's the difference between NAC, NAD+, and NAM/NMN? They all seem similar.
These compounds sound similar but are completely different molecules with different functions. (1) NAC (N-acetylcysteine) is a modified amino acid used as a glutathione precursor and antioxidant — the subject of this page. (2) NAD+ (nicotinamide adenine dinucleotide) is a coenzyme derived from vitamin B3 (niacin) that shuttles electrons in redox reactions, supports sirtuin enzyme function, and powers DNA repair — see NAD. (3) NMN (nicotinamide mononucleotide) is a NAD+ precursor that is directly incorporated into NAD+ biosynthesis — see NMN. (4) NR (nicotinamide riboside) is another NAD+ precursor, often compared to NMN. (5) Nicotinamide (NAM) is vitamin B3 itself, the most downstream NAD+ precursor. The NAC/NAD pathways intersect at redox biology — both support cellular antioxidant capacity — but through completely different molecular mechanisms. NAC supports the thiol (GSH-based) antioxidant system; NAD+ and its precursors support the NADPH-dependent antioxidant system (via glutathione reductase and thioredoxin reductase, both of which use NADPH) and the sirtuin-mediated stress response. The two systems are complementary, and both are legitimate supplementation targets for different purposes, though their evidence bases differ substantially in strength.
Should I take NAC if I'm healthy and just want general longevity benefits?
The honest answer is: probably, with the caveat that the marginal benefit in a healthy, well-nourished individual is modest. Evidence for NAC's benefits is strongest in clinical contexts with clear GSH depletion (acetaminophen overdose, COPD, specific psychiatric conditions, male infertility, PCOS) and weakest in healthy-adult longevity contexts. The mechanistic rationale for longevity use is coherent: GSH declines with age, GSH depletion is associated with increased oxidative stress and inflammation, and NAC restores GSH synthesis capacity. But 'mechanistically plausible' is not the same as 'proven to extend healthspan in healthy humans.' If you are a healthy adult with good nutrition, adequate protein intake (which provides cysteine from whole foods), good sleep, regular exercise, and low psychosocial stress, your baseline GSH status is probably adequate and NAC supplementation provides modest benefit. If you are older (over 60), recovering from illness, under chronic stress, drinking alcohol regularly, or otherwise GSH-challenged, the marginal benefit may be meaningful. The conservative position: 600 mg NAC once daily is cheap (pennies per day), safe (40+ years of evidence), and has mechanistic rationale — a reasonable addition to a longevity regimen for those over 50 or with specific risk factors. Do not treat it as a magic longevity bullet; treat it as a modest supplement that may add small benefit within a larger healthspan framework that prioritizes sleep, exercise, nutrition, social connection, and stress management.
Research Tools
Related Compounds
View AllSide-by-Side Comparisons
All ComparisonsCompare NAC head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
